Metharbital

Metharbital
Clinical data
Other namesEndiemal, metharbitone, methobarbitone[1]
Routes of
administration		By mouth (tablets)
ATC code
Legal status
Legal status
Identifiers
  • 5,5-Diethyl-1-methylpyrimidine-2,4,6(1H,3H,5H)-trione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.011 Edit this at Wikidata
Chemical and physical data
FormulaC9H14N2O3
Molar mass198.222 g·mol−1
3D model (JSmol)
  • O=C1N(C(=O)NC(=O)C1(CC)CC)C
  • InChI=1S/C9H14N2O3/c1-4-9(5-2)6(12)10-8(14)11(3)7(9)13/h4-5H2,1-3H3,(H,10,12,14) checkY
  • Key:FWJKNZONDWOGMI-UHFFFAOYSA-N checkY
  (verify)

Metharbital was patented in 1905 by Emil Fischer working for Merck.[2] It was marketed as Gemonil by Abbott Laboratories. It is a barbiturate anticonvulsant, used in the treatment of epilepsy.[3][4] It has similar properties to phenobarbital.

  1. ^ "Metharbital". The Comparative Toxicogenomics Database.
  2. ^ US 782742, Fischer E, "Trisubstituted barbituric acids and process of making them.", issued 14 February 1905, assigned to E. Merck 
  3. ^ Shorvon SR, Fish DR, Perucca E, Dodson WE, eds. (2004). The Treatment of Epilepsy (2nd ed.). Blackwell. ISBN 0-632-06046-8.
  4. ^ Resor SR (1991). The Medical Treatment of Epilepsy. Marcel Dekker. ISBN 0-8247-8549-5.